In Brief: Bristol-Myers Squibb
This article was originally published in The Gray Sheet
Bristol-Myers Squibb: Zimmer subsidiary acquires craniofacial implant line from Anspach Fixation Devices, Inc. The line, which will be marketed under the Zimmer name, consists of "micro-sized bone titanium plates and bone screws for craniofacial/maxillofacial and neurological bone reconstruction," Zimmer says. The product line will complement Zimmer's ECT Internal Fracture Fixation, the firm says, and "will increase the number of indications that trauma surgeons can address with Zimmer systems." Zimmer also plans to apply the technology to other subspecialties such as hand surgery and small-bone fixation...
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.